Read the free preview copy or click on the cover to buy with FREE shipping worldwide.

Rob McInnes on IP

"Thirty years ago, only 20% of a typical listed company's value would be represented by intan- gible assets, today the figure is closer to 80%. It's arguable that IP is now the main source of sustainable competitive advantage for almost all businesses."
Rob McInness, Partner
Spruson & Ferguson
(Austr. Innov. 2008 p51) 


IP (noun, abbrev. for)
in·tel·lec·tu·al prop·er·ty

Property or intangible asset arising from a novel creation of the mind, such as a design, manuscript, innovation or invention which may be protected by a patent, copyright, trademark, etc.

Connect with me on Maven


“Matt's skills at interfacing between scientist and business are excellent. I would highly recommend him to anyone wishing to learn and get the best deal from another party.”
David Andrews, CEO
Woolcock Institute

Dispute Resolution

“Matt achieved great results with minimal investment requirements. The dispute is resolved and Agreon is very pleased with the out- comes.”
Brian Brannigan,
CEO of Agreon

« Working for a Mature Company? | Main | Research Organisations, Universities, CRCs, etc. »

Investors & Angels

Common Challenges:
Investment terms, Intellectual Property, Governance, Contracts

Investors often struggle to engage effectively with inventors and academic organisations. IP issues and the resulting processes and negotiations can be drawn out and painful for both sides. IPR can help with:

  • Technology assessment
  • IP due diligence
  • IP strategy 
  • Company Director services
  • Dispute resolution
  • Commercialisation and business development services
  • Interim CEO / COO roles
  • Negotiations with inventors, universities and research organisations

IPR can provide an unbiased assessment of the commercial opportunity and our experience and expertise on both sides of the fence might help to bridge the gap when it comes to getting it off the ground. Why not contact us to review the issues?

Past Engagements: Kingsbury Capital, Cancer Research Ventures (UK), Unisearch and private investors.